Aim: To perform a chemoreactome modeling of the pharmacological central effects of 4 non-steroidal anti-inflammatory drugs (NSAIDs): dexketoprofen, ketoprofen, aceclofenac, lornoxicam.
Material And Methods: An analysis of the pharmacological spectrum of the central action of dexketoprofen, ketoprofen, aceclofenac and lornoxicam was based on the chemoinformatic approach, which compared drug-likeness properties with public and commercial software.
Results: The effectiveness of NSAIDs is related to the inhibition of cannabinoid receptors CB-1, the vanilloid receptor TRPV1, NMDA and AMPA receptors and of the GABA reuptake transporter, with dexketoprofen being the most effective inhibitor. The safety of the central effects of NSAID is due to weak interactions of the NSAIDs studied with opioid, adrenergic, serotonin and dopamine receptors. Chemoreactome modeling made it possible to compare the particulars of the effects of the studied NSAIDs on experimental pain and cramps.
Conclusion: Inhibition of CB-1, TRPV1, NMDA, AMPA, GABA transporter by the NSAID molecules corresponds to a decrease in the intensity of nociceptive signals. A weak intervention of the studied NSAIDs in opioid, adrenergic, serotonin and dopaminergic neurotransmission corresponds to a decrease in the central side-effects of NSAIDs and to a lessened antagonism of these NSAIDs towards exogenous and endogenous opioids.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro202012001170 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Public Health.
Alzheimers Dement
December 2024
Erasmus University Medical Center, Rotterdam, Zuid-Holland, Netherlands.
Background: Non-steroidal anti-inflammatory (NSAID) medication are suggested to have beneficial effects in the prevention of Alzheimer's disease, due to anti-inflammatory and possibly amyloid-lowering properties. However, the results of observational studies and randomized-controlled trials have been inconsistent, and duration and dose-response relationships are still unclear.
Method: We included 11,745 dementia-free participants from the prospective population-based Rotterdam Study (59.
Background: Alzheimer's Disease (AD) is a complex neurodegenerative disease characterized by multiple etiologies that remains without a cure. Diabetes, dyslipidemia, hypertension, and inflammation are well-known risk factors for AD, and FDA-approved therapeutics for these conditions have been associated with a reduced risk of developing AD. This study aims to evaluate the impact of diabetes medications (DBMD), lipid-lowering (LIPL), antihypertensive (AHTN), and non-steroidal anti-inflammatory (NSD) therapeutics, alone or combined, on cognitive performance in an AD population.
View Article and Find Full Text PDFBackground: Dementia is a growing global public health challenge. Previous meta-analyses have found that systemic medications may modulate dementia risk. We aimed to provide an overview of this evidence.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Newcastle University, Newcastle Upon Tyne, United Kingdom.
Background: Evidence from epidemiological and clinical studies of the effect of anti-inflammatory medication on dementia risk has been mixed. Over the past two decades there has been recurring epidemiological evidence that the use of NSAID's for chronic inflammatory conditions is associated with a lower incidence of dementia.
Method: Cognitive Function and Ageing Study (CFAS) undertook baseline interviews in populations aged 65+ years in England and Wales (1989-1994).
A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond.
Electrolyte Blood Press
December 2024
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Diabetic kidney disease (DKD) is a prevalent and complex disease among patients with diabetes in Korea, requiring comprehensive treatment strategies. Traditional management strategies targeting blood pressure, blood sugar, lipid, and lifestyles are foundational approaches of DKD treatment, each of them still holding importance in current paradigms. The four pillars, renin-angiotensin system(RAS) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and non-steroidal mineralocorticoid receptor antagonists (nsMRA) can enhance DKD treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!